IC
AMLX icon

Ikarian Capital’s Amylyx Pharmaceuticals AMLX Stock Holding History

Ikarian Capital’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-186,400
Closed -$529K – 116
2024
Q1 		$529K Buy
+186,400
New +$2.44M 0.06% 117

Other funds holding AMLX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Ikarian Capital's AMLX Position: Q1 2025 in Review

Ikarian Capital sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2025, closing a stake of 201,187 shares — an estimated $760K sold.

Ikarian Capital first reported a position in AMLX in Q1 2022 and held it in 8 quarters. The position peaked at $12.9M in Q4 2023. 136 funds tracked by Wall St. Rank hold AMLX as of Q1 2025.

  • Ikarian Capital reported no remaining Amylyx Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Ikarian Capital sold 201,187 Amylyx Pharmaceuticals shares in Q1 2025, an estimated $760K.
  • Ikarian Capital first reported a position in Amylyx Pharmaceuticals in Q1 2022 and held it in 8 quarters.
  • Ikarian Capital's Amylyx Pharmaceuticals position peaked at $12.9M in Q4 2023.
  • 136 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2025.

Based on Ikarian Capital's 13F filing for Q1 2025, filed 15 May 2025.